Stereotactic radiotherapy (SRT) for differentiated thyroid cancer (DTC) oligometastases: an AIRO (Italian association of radiotherapy and clinical oncology) systematic review
Authors:
- 8 April 2022
- journal article
- review article
- Published by Springer Nature in La radiologia medica
- Vol. 127 (6) , 681-689
Abstract
Purpose The aim of this systematic review was to examine efficacy of stereotactic radiotherapy (SRT) in patients with oligometastatic thyroid cancer. Materials and methods A systematic search was conducted by means of PubMed, Scopus, and Cochrane library. ClinicalTrials.gov was searched for ongoing or recently completed trials, and PROSPERO was searched for ongoing or recently completed systematic reviews. We analyzed only clinical studies as full text carried out on patients with oligometastatic thyroid cancer treated with SRT. Conference papers, surveys, letters, editorials, book chapters, and reviews were excluded. Time of publication was restricted to the years 1990–2021. Results The number of evaluated patients was 146 (267 lesions), and the median age was 58 years. The median 1-year local control (LC) was 82% (range 67.0%–97.1%); the median disease-free survival (DFS) was 12 months (range 4–53); the median 1-year overall survival was 72% (range 66.6%–85.0%); the 3-year cancer-specific survival was 75.0%; and the 4-year cancer-specific survival was 37.5%. No grade 3–5 acute toxicity was reported. No late effects were recorded. Conclusions SRT for oligometastases from thyroid cancer as salvage therapy is well tolerated and yields high rates of LC and prolonged DFS.Keywords
Funding Information
- 5x1000 per la Ricerca Sanitaria (no grant number provided)
- Associazione Italiana per la Ricerca sul Cancro (21879)
- Italian Ministry of Health (RCR-2020-23670066)
This publication has 50 references indexed in Scilit:
- Vandetanib in Patients With Locally Advanced or Metastatic Medullary Thyroid Cancer: A Randomized, Double-Blind Phase III TrialJournal of Clinical Oncology, 2012
- Fiducial-free CyberKnife stereotactic body radiation therapy (SBRT) for single vertebral body metastases: acceptable local control and normal tissue tolerance with 5 fraction approachFrontiers in Oncology, 2012
- Stereotactic Body Radiosurgery for Spinal Metastatic Disease: An Evidence-Based ReviewInternational Journal of Surgical Oncology, 2011
- Metastatic Dormancy and Progression in Thyroid Cancer: Targeting Cells in the Metastatic FrontierThyroid®, 2011
- Adjuvant Whole-Brain Radiotherapy Versus Observation After Radiosurgery or Surgical Resection of One to Three Cerebral Metastases: Results of the EORTC 22952-26001 StudyJournal of Clinical Oncology, 2011
- Correlation of Local Failure With Measures of Dose Insufficiency in the High-Dose Single-Fraction Treatment of Bony MetastasesInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2010
- Risk of Fracture After Single Fraction Image-Guided Intensity-Modulated Radiation Therapy to Spinal MetastasesJournal of Clinical Oncology, 2009
- Differentiated Thyroid Carcinoma with Distant Metastases: Probability of Survival and Its Predicting FactorsCancer Biotherapy and Radiopharmaceuticals, 2007
- Partial volume tolerance of the spinal cord and complications of single‐dose radiosurgeryCancer, 2006
- Management of brain metastases from thyroid carcinomaCancer, 2003